Biogen Inc agreed to pay $900 million to settle allegations about improper physician payments; the American Cancer Society warns that fertility preservation for patients with cancer is at risk after the overturn of Roe v Wade; the Supreme Court will hear a case about Medicaid recipients’ ability to sue their providers.
Biogen Inc has agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid through kickback payments to physicians for prescribing Biogen drugs. This payment resolves a lawsuit that was filed by a former Biogen employee under the False Claims Act. The lawsuit alleged that Biogen paid physicians kickbacks to entice them to prescribe Biogen’s drugs for multiple sclerosis from January 1, 2009, to March 18, 2014. Biogen will be paying the United States government $843,805,187 and 15 states will receive $56,194,813.
The American Cancer Society warned that fertility preservation options for patients with cancer could be at risk in a post–Roe v Wade world. Gene testing and storage and disposal of embryos could be areas where restrictions are imposed in the future, according to the American Cancer Society. Researchers found that of more than 120,000 patients aged 15 to 44 years who were diagnosed with cancer in 2018, 68% of them needed fertility preservation services. Of those, there were 32,000 patients who lived in the 22 states where abortion bans exist or are expected to be passed.
The Supreme Court plans to hear a case on Medicaid recipients’ ability to sue providers, which could potentially open the door to further rollback of the program’s benefits. The decision will determine whether tens of millions of beneficiaries of public welfare programs can sue their providers if their essential needs like health care and food are at risk, which would be more efficient than waiting on the federal government. Conservative judges and lawyers have argued that health care providers or individuals should not be able to sue in cases of Medicaid coverage. Arguments in the current case, Health and Hospital Corp v Talevski, are set to start on November 8.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More